These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 29188583)

  • 1. Infusions of Epstein-Barr virus-specific cytotoxic T lymphocytes as post-remission therapy in high-risk post-transplant lymphoproliferative disorder patients: report of two cases.
    Kim N; Sohn HJ; Oh JH; Jeon YW; Lee HJ; Cho HI; Chung BH; Yang CW; Kim TG; Cho SG
    Int J Hematol; 2018 May; 107(5):596-603. PubMed ID: 29188583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Establishment and operation of a Good Manufacturing Practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease.
    Vickers MA; Wilkie GM; Robinson N; Rivera N; Haque T; Crawford DH; Barry J; Fraser N; Turner DM; Robertson V; Dyer P; Flanagan P; Newlands HR; Campbell J; Turner ML
    Br J Haematol; 2014 Nov; 167(3):402-10. PubMed ID: 25066775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells.
    Haque T; Wilkie GM; Taylor C; Amlot PL; Murad P; Iley A; Dombagoda D; Britton KM; Swerdlow AJ; Crawford DH
    Lancet; 2002 Aug; 360(9331):436-42. PubMed ID: 12241714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication.
    Comoli P; Labirio M; Basso S; Baldanti F; Grossi P; Furione M; Viganò M; Fiocchi R; Rossi G; Ginevri F; Gridelli B; Moretta A; Montagna D; Locatelli F; Gerna G; Maccario R
    Blood; 2002 Apr; 99(7):2592-8. PubMed ID: 11895798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease.
    Khanna R; Bell S; Sherritt M; Galbraith A; Burrows SR; Rafter L; Clarke B; Slaughter R; Falk MC; Douglass J; Williams T; Elliott SL; Moss DJ
    Proc Natl Acad Sci U S A; 1999 Aug; 96(18):10391-6. PubMed ID: 10468618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epstein-Barr virus-specific cytotoxic T-lymphocytes for adoptive immunotherapy of post-transplant lymphoproliferative disease.
    Burns DM; Crawford DH
    Blood Rev; 2004 Sep; 18(3):193-209. PubMed ID: 15183903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EBV-specific cytotoxic T lymphocytes for refractory EBV-associated post-transplant lymphoproliferative disorder in solid organ transplant recipients: a systematic review.
    Liu JY; Zhang JM; Zhan HS; Sun LY; Wei L
    Transpl Int; 2021 Dec; 34(12):2483-2493. PubMed ID: 34510581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytotoxic T-lymphocyte therapy for post-transplant lymphoproliferative disorder after solid organ transplantation in children.
    Chiou FK; Beath SV; Wilkie GM; Vickers MA; Morland B; Gupte GL
    Pediatr Transplant; 2018 Mar; 22(2):. PubMed ID: 29388302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term Outcome of Extranodal NK/T Cell Lymphoma Patients Treated With Postremission Therapy Using EBV LMP1 and LMP2a-specific CTLs.
    Cho SG; Kim N; Sohn HJ; Lee SK; Oh ST; Lee HJ; Cho HI; Yim HW; Jung SE; Park G; Oh JH; Choi BO; Kim SW; Kim SW; Chung NG; Lee JW; Hong YS; Kim TG
    Mol Ther; 2015 Aug; 23(8):1401-1409. PubMed ID: 26017177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment options for post-transplant lymphoproliferative disorder and other Epstein-Barr virus-associated malignancies.
    Davis JE; Moss DJ
    Tissue Antigens; 2004 Apr; 63(4):285-92. PubMed ID: 15009802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LMP1-specific cytotoxic T cells for the treatment of EBV-related post-transplantation lymphoproliferative disorders.
    Hong J; Ni J; Ruan M; Yang M; Dong Q; Li Q
    Int J Hematol; 2020 Jun; 111(6):851-857. PubMed ID: 32162095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adoptive cellular immunotherapy for EBV lymphoproliferative disease.
    Heslop HE; Rooney CM
    Immunol Rev; 1997 Jun; 157():217-22. PubMed ID: 9255632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epstein-Barr virus, B cell lymphoproliferative disease, and SCID mice: modeling T cell immunotherapy in vivo.
    Johannessen I; Bieleski L; Urquhart G; Watson SL; Wingate P; Haque T; Crawford DH
    J Med Virol; 2011 Sep; 83(9):1585-96. PubMed ID: 21739450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adoptive transfer of epstein-barr virus (EBV) nuclear antigen 1-specific t cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation.
    Icheva V; Kayser S; Wolff D; Tuve S; Kyzirakos C; Bethge W; Greil J; Albert MH; Schwinger W; Nathrath M; Schumm M; Stevanovic S; Handgretinger R; Lang P; Feuchtinger T
    J Clin Oncol; 2013 Jan; 31(1):39-48. PubMed ID: 23169501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases.
    Styczynski J; Einsele H; Gil L; Ljungman P
    Transpl Infect Dis; 2009 Oct; 11(5):383-92. PubMed ID: 19558376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes.
    Comoli P; Pedrazzoli P; Maccario R; Basso S; Carminati O; Labirio M; Schiavo R; Secondino S; Frasson C; Perotti C; Moroni M; Locatelli F; Siena S
    J Clin Oncol; 2005 Dec; 23(35):8942-9. PubMed ID: 16204009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EBV and posttransplantation lymphoproliferative disease: what to do?
    Zimmermann H; Trappe RU
    Hematology Am Soc Hematol Educ Program; 2013; 2013():95-102. PubMed ID: 24319169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autologous lymphokine-activated killer cell therapy of Epstein-Barr virus-positive and -negative lymphoproliferative disorders arising in organ transplant recipients.
    Nalesnik MA; Rao AS; Furukawa H; Pham S; Zeevi A; Fung JJ; Klein G; Gritsch HA; Elder E; Whiteside TL; Starzl TE
    Transplantation; 1997 May; 63(9):1200-5. PubMed ID: 9158009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins.
    Bollard CM; Gottschalk S; Torrano V; Diouf O; Ku S; Hazrat Y; Carrum G; Ramos C; Fayad L; Shpall EJ; Pro B; Liu H; Wu MF; Lee D; Sheehan AM; Zu Y; Gee AP; Brenner MK; Heslop HE; Rooney CM
    J Clin Oncol; 2014 Mar; 32(8):798-808. PubMed ID: 24344220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial.
    Haque T; Wilkie GM; Jones MM; Higgins CD; Urquhart G; Wingate P; Burns D; McAulay K; Turner M; Bellamy C; Amlot PL; Kelly D; MacGilchrist A; Gandhi MK; Swerdlow AJ; Crawford DH
    Blood; 2007 Aug; 110(4):1123-31. PubMed ID: 17468341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.